Showing 1571-1580 of 1692 results for "".
- Pimavanserin Reduce Risks of Dementia-Related Psychotic Relapse Almost Threefoldhttps://practicalneurology.com/news/pimavanserin-reduce-risks-of-dementia-related-psychotic-relapse-almost-threefold/2469089/In top-line results from the pivotal phase 3 HARMONY (NCT03325556) study, treatment with pimavanserin vs placebo (Nuplazid, Acadia Pharmaceuticals, San Diego, CA) reduced risk of psychotic relapse by 2.8 fold (HR = 0.353; one-sided
- $1.5 Million in Community Grant Funding from The Parkinson's Foundationhttps://practicalneurology.com/news/15-million-in-community-grant-funding-from-the-parkinsons-foundation/2468771/More than $1.5 million in community grants from The Parkinson's Foundation were announced. The grants will support education, wellness, and local health programs that address unmet needs for people living with Parkinson’s disease (PD) and their loved ones. The grants range from $5,000 t
- A Wide Range of Cenobamate Doses Linked to Seizure Freedomhttps://practicalneurology.com/news/a-wide-range-of-cenobamate-doses-linked-to-seizure-freedom/2470656/Flexible dosing with Xcopri (cenobamate; SK Life Science, Paramus, NJ) may allow for optimal seizure reduction, according to data presented at the American Epilepsy Society (AES) 2024 Annual Meeting. Results from the post-hoc analysis of an open-label, phase 3 study demonstrate that a wide range
- Once-Daily Pill Approved to Treat Forms of Astrocytoma and Oligodendrogliomahttps://practicalneurology.com/news/once-daily-pill-approved-to-treat-forms-of-astrocytoma-and-oligodendroglioma/2470553/The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib; Servier, Boston, MA) for the treatment of adults and children aged ≥12 years with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutati
- Eisai Initiates Formal Application for Subcutaneous Leqembi Alzheimer Disease Treatmenthttps://practicalneurology.com/news/eisai-initiates-formal-application-for-subcutaneous-leqembi-alzheimer-disease-treatment/2470474/Eisai announced the initiation of the rolling submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA) subcutaneous (SC) autoinjector for weekly maintenance dosing to treat individuals wi
- Dr. Anthony Lang Presents Novel SynNeurGe Model of Parkinson Disease Identificationhttps://practicalneurology.com/news/dr-anthony-lang-presents-novel-synneurge-model-of-parkinson-disease-identification/2470321/Dr. Anthony Lang, Professor of Neurology and Jack Clark Chair for Parkinson’s Disease Research at the University of Toronto, presented a new model for identifying Parkinson disease (PD) at the 26th World Congress of Neurology. The new model, SynNeurGe, is a framework consisting of 3 distinc
- FDA Clears Orally Inhaled DHE Formulation for Clinical Investigation as Potential Treatment for Acute Migrainehttps://practicalneurology.com/news/fda-clears-orally-inhaled-dhe-formulation-for-clinical-investigation-as-potential-treatment-for-acute-migraine/2470301/Pulmatrix’s (Bedford, MA) investigational new drug (IND) application for PUR3100 (dihydroergotamine [DHE] mesylate inhalation powder) has been cleared by the Food and Drug Administration (FDA), authorizing further investigation into this potential therapy for acute migraine. PUR3100 consist
- New Analysis from N-MOmentum Study Shows UPLIZNA Treatment Reduced Spinal Cord Lesion Formation in Patients with NMOSDhttps://practicalneurology.com/news/new-analysis-from-n-momentum-study-shows-uplizna-treatment-reduced-spinal-cord-lesion-formation-in-patients-with-nmosd/2470235/According to analysis of MRI data from the N-MOmentum clinical trial (NCT02200770), treatment with Uplizna (inebilizumab-cdon, Horizon Therapeutics PLC, Dublin, Ireland) reduced subclinical trans
- First Treatment for Genetic Form of Amyotrophic Lateral Sclerosis Approved by FDAhttps://practicalneurology.com/news/first-treatment-for-genetic-form-of-amyotrophic-lateral-sclerosis-approved-by-fda/2470172/The Food and Drug Administration (FDA) approved the first treatment for amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. Tofersen (QALSODY; Biogen, Cambridg
- Intramuscular Formulation of Depot Glatiramer Acetate, Dosed Monthly, Reduced Annualized Relapse Rate of Multiple Sclerosishttps://practicalneurology.com/news/glatiramer-acetate-reduces-annualized-relapse-rate-in-individuals-with-relapsing-multiple-sclerosis/2470030/In a phase 3 study (NCT04121221), a long acting glatiramer acetate (GA depot) (Mapi Pharma, Ziona, Israel) statistically significantly reduced the annualized relapse rate (ARR) by 30.1% compared with